Immix Biopharma (IMMX) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Verastem (VSTM) over the past year, gaining 278.1% versus a loss of 8.2%. Immix Biopharma is the larger company by market cap ($772.7 million vs $727.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | VSTM |
|---|---|---|
| Share price | $9.32 | $8.03 |
| Market cap | $772.66M | $727.22M |
| 1-day change | -1.79% | -2.84% |
| YTD return | +81.45% | +7.06% |
| 1-year return | +278.09% | -8.17% |
| 5-year return | — | -75.05% |
| EPS (TTM) | $-0.88 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.10 | $10.82 |
| 52-week low | $2.31 | $3.43 |
| Distance from 52-week high | -38.28% | -25.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.73% | +82.69% |
| Average volume | 1.65M | 2.29M |
| Shares outstanding | 82.90M | 90.56M |
| Employees | 21 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed VSTM by 286.3 percentage points over the past year.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
IMMX vs VSTM FAQ
Which is bigger, Immix Biopharma or Verastem?
Immix Biopharma (IMMX) is larger, with a market capitalization of $772.66M compared with $727.22M for Verastem (VSTM).
Which stock has performed better over the past year, IMMX or VSTM?
IMMX returned +278.09% over the past 12 months, compared with -8.17% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Immix Biopharma and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.